Zo­genix rock­ets up as PhI­II study of­fers im­pres­sive da­ta on Dravet syn­drome, vault­ing over a ri­val

Zo­genix of­fered in­vestors ex­act­ly the kind of gourmet da­ta they were look­ing for this morn­ing with a clean sweep of promis­ing da­ta for its late-stage drug ZX008, de­signed to tack­le a se­vere form of child­hood epilep­sy. And the news pow­ered a big spike in its share price $ZGNX as Wall Street con­tin­ues to show­er re­wards on clear suc­cess­es.

The first of two Phase III stud­ies for this drug, re­searchers say they tracked a clear dose-de­pen­dent re­sponse for this treat­ment, with a dra­mat­ic drop in the rate of seizures ex­pe­ri­enced by pa­tients with Dravet syn­drome.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.